Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

Inclusion Criteria: * Phase I only: Histologically or cytologically confirmed solid tumors that are advanced and refractory to or lack life-prolonging treatments; patients with histologically or cytologically confirmed renal cell carcinoma and hepatocellular carcinoma will be eligible * Phase II: Histologically or cytologically proven metastatic adenocarcinoma of pancreas that had progressed after one prior gemcitabine containing regimen, or progressed within 6 months of the completion of gemcitabine containing adjuvant regimen * Patients must have measurable or assessable disease * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Adequate hematological, renal and liver functions as determined by the following: * Absolute neutrophil count (ANC) \> 1500 cells/mm\^3 * Hemoglobin \>= 9g/dL * Platelets \>= 100,000 cells/mm\^3 * Serum creatinine within institutional upper limit of normal (ULN) OR \>= 60mll/min for patients with creatinine levels above institutional ULN * Bilirubin =\< 1.5 x ULN * Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) =\< 2.5 times ULN (\< 5 x ULN for patients with abnormal values attributable to liver metastases) * Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\]) =\< 2.5 times ULN (\< 5 x ULN for patients with abnormal values attributable to liver metastases) * International normalized ratio (INR) =\< 1.5 (Anticoagulation is allowed if target INR =\< 1.5 on a stable dose o…